{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:16:16Z","timestamp":1791260176234,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal de Mycologie M\u00e9dicale"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.mycmed.2018.02.002","type":"journal-article","created":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T14:03:37Z","timestamp":1521209017000},"page":"15-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity"],"prefix":"10.1016","volume":"28","author":[{"given":"M.-P.","family":"Ledoux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Nivoix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Herbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mycmed.2018.02.002_bib0260","unstructured":"Food & Drug Administration. Cresemba. Full prescribing information. https:\/\/wwwaccessdatafdagov\/drugsatfda_docs\/label\/2015\/207500Orig1s000lblpdf2015."},{"key":"10.1016\/j.mycmed.2018.02.002_bib0265","unstructured":"European Medicines Agency. Cresemba. Summary of product characteristics. http:\/\/wwwemaeuropaeu\/ema\/indexjsp?curl=pages\/medicines\/human\/medicines\/002734\/human_med_001907jsp&mid=WC0b01ac058001d1242015."},{"key":"10.1016\/j.mycmed.2018.02.002_bib0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.mycmed.2018.02.005","article-title":"Isavuconazole: a new broad-spectrum azole. Part 1: in vitro activity","author":"Denis","year":"2018","journal-title":"J Med Mycol"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0275","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jac\/dkn431","article-title":"Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei","volume":"63","author":"Majithiya","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0280","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1128\/AAC.01601-08","article-title":"Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect","volume":"53","author":"Warn","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0285","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1128\/AAC.01354-13","article-title":"Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model","volume":"57","author":"Lepak","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0290","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1093\/jac\/dkw098","article-title":"Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints","volume":"71","author":"Kovanda","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0295","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1128\/AAC.02665-15","article-title":"Pharmacokinetics and concentration-dependent efficacy of isavuconazole for treatment of experimental invasive pulmonary aspergillosis","volume":"60","author":"Petraitis","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0300","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1128\/AAC.04907-14","article-title":"Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model","volume":"59","author":"Seyedmousavi","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0305","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/jac\/dkl396","article-title":"Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus","volume":"58","author":"Warn","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0310","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1128\/AAC.02301-13","article-title":"Isavuconazole therapy protects immunosuppressed mice from mucormycosis","volume":"58","author":"Luo","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0315","first-page":"61","article-title":"Prophylaxis with isavuconazole or posaconazole protects immunosuppressed mice from pulmonary mucormycosis","author":"Gebremariam","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0320","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/jac\/dkw433","article-title":"Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis","volume":"72","author":"Gebremariam","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0325","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1128\/AAC.50.1.279-285.2006","volume":"50","author":"Schmitt-Hoffmann","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0330","doi-asserted-by":"crossref","first-page":"572","DOI":"10.5414\/CP202434","article-title":"Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH","volume":"54","author":"Schmitt-Hoffmann","year":"2016","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0335","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/cpdd.376","article-title":"Two phase 1, open-label, mass balance studies to determine the pharmacokinetics of 14 C-labeled isavuconazonium sulfate in healthy male volunteers","volume":"7","author":"Townsend","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0340","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1128\/AAC.04569-14","article-title":"Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study","volume":"59","author":"Cornely","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0345","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01292-17","article-title":"Tissue distribution and elimination of isavuconazole following single and repeat oral-dose administration of isavuconazonium sulfate to rats","volume":"61","author":"Schmitt-Hoffmann","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0350","series-title":"Successful treatment of contaminated epidural steroid associated fungal meningitis with isavuconazole","author":"Everson","year":"2015"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0355","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cpdd.283","article-title":"Pharmacokinetic and pharmacodynamic evaluation of the drug-drug interaction between isavuconazole and warfarin in healthy subjects","volume":"6","author":"Desai","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0360","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/cpdd.284","article-title":"Pharmacokinetic assessment of drug-drug interactions of isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults","volume":"6","author":"Groll","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0365","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12751","article-title":"Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4","volume":"19","author":"Groll","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0370","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cpdd.285","article-title":"Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interactions of isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol\/norethindrone in healthy adults","volume":"6","author":"Townsend","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0375","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00970-17","article-title":"Effects of isavuconazole on the plasma concentrations of tacrolimus among solid organ transplant patients","volume":"61","author":"Rivosecchi","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0380","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/cpdd.280","article-title":"Pharmacokinetic interactions between isavuconazole and the drug transporter substrates atorvastatin, digoxin, metformin, and methotrexate in healthy subjects","volume":"6","author":"Yamazaki","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0385","doi-asserted-by":"crossref","first-page":"i12","DOI":"10.1093\/jac\/dkx029","article-title":"Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations","volume":"72","author":"Stott","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0390","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01034-17","article-title":"Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi","volume":"61","author":"Desai","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0395","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0400","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/cid\/ciu911","volume":"60","author":"Herbrecht","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0405","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1128\/AAC.02819-15","article-title":"Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0410","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0415","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.amjoto.2015.12.003","article-title":"Successful Isavuconazole therapy in a patient with acute invasive fungal rhinosinusitis and acquired immune deficiency syndrome","volume":"37","author":"Ahmed","year":"2016","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0420","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s15010-013-0552-6","article-title":"Successful isavuconazole salvage therapy in a patient with invasive mucormycosis","volume":"42","author":"Ervens","year":"2014","journal-title":"Infection"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0425","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.mmcr.2016.03.002","article-title":"Isavuconazole as salvage therapy for mucormycosis","volume":"11","author":"Graves","year":"2016","journal-title":"Med Mycol Case Rep"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0430","first-page":"1925070","article-title":"Successful treatment of recurrent pulmonary mucormycosis in a renal transplant patient: a case report and literature review","volume":"2017","author":"Martin","year":"2017","journal-title":"Case Rep Transplant"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0435","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/JCM.03176-13","article-title":"Isavuconazole treatment of a patient with disseminated mucormycosis","volume":"52","author":"Peixoto","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0440","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/cid\/ciw305","article-title":"Isavuconazole treatment of Cryptococcosis and dimorphic mycoses","volume":"63","author":"Thompson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0445","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1128\/AAC.04586-14","article-title":"A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis","volume":"59","author":"Viljoen","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0450","series-title":"Isavuconazole versus caspofungin in the treatment of candidaemia and other invasive Candida infections: the ACTIVE trial. 26th European Congress of clinical microbiology and infectious diseases. Amsterdam, Netherlands","author":"Kullberg","year":"2016"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0455","series-title":"Efficacy of isavuconazole (ISAV) in patients with central nervous system (CNS) invasive fungal disease (IFD)","author":"Schwartz","year":"2017"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0460","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/cid\/ciw585","article-title":"Real-life use of isavuconazole in patients intolerant to other azoles","volume":"63","author":"Ordaya","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0465","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/cpt.620","article-title":"QT interval shortening with isavuconazole: in vitro and in vivo effects on cardiac repolarization","volume":"101","author":"Keirns","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0470","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1476-5381.2009.00191.x","article-title":"Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives","volume":"159","author":"Shah","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0475","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12712","article-title":"Use of isavuconazole in a patient with voriconazole-induced QTc prolongation","volume":"19","author":"Trang","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0480","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3111\/13696998.2016.1164175","article-title":"Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial","volume":"19","author":"Horn","year":"2016","journal-title":"J Med Econ"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0485","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s12325-016-0443-1","article-title":"Cost-effectiveness analysis of isavuconazole vs voriconazole as first-line treatment for invasive aspergillosis","volume":"34","author":"Harrington","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0490","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2217\/fmb-2016-0231","article-title":"The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK","volume":"12","author":"Bagshaw","year":"2017","journal-title":"Future Microbiol"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0495","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/cid\/ciw444","article-title":"Executive summary: practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0500","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0505","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.mycmed.2018.02.002_bib0510","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/cpdd.282","article-title":"Pharmacokinetic interaction between isavuconazole and a fixed-dose combination of lopinavir 400mg\/ritonavir 100mg in healthy subjects","volume":"6","author":"Yamazaki","year":"2017","journal-title":"Clin Pharmacol Drug Dev"}],"container-title":["Journal de Mycologie M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1156523317304158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1156523317304158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:19:02Z","timestamp":1761110342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1156523317304158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S1156523317304158"],"URL":"https:\/\/doi.org\/10.1016\/j.mycmed.2018.02.002","relation":{},"ISSN":["1156-5233"],"issn-type":[{"value":"1156-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity","name":"articletitle","label":"Article Title"},{"value":"Journal de Mycologie M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mycmed.2018.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}